Aqueous extract of erigeron annuus ameliorates OVA-induced atopic dermatitis-like skin lesions through modulation of Th2-mediated immune responses and MAPK signaling
Oct 2026· Pharmaceutical Biology· Vol 64, pp. 1125 - 1142· 0 citations· 61 references
Medicine
TL;DR
EA attenuated OVA-induced atopic dermatitis-like inflammation in association with improved epidermal barrier function, reduced Th2-associated immune responses, and attenuated MAPK signaling, and warrants further investigation as a plant-derived candidate for complementary intervention in atopic dermatitis.
Abstract
Abstract Context Atopic dermatitis is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction and dysregulated type 2 helper T cell (Th2)-mediated immune responses. Erigeron annuus (L.) Desf. is traditionally used for inflammatory conditions, but its effects on atopic dermatitis remain unclear. Objective This study evaluated the protective effects of E. annuus aqueous extract (EA) and associated mechanisms. Materials and methods Atopic dermatitis-like lesions were induced in 5-week-old female BALB/c mice by repeated epicutaneous ovalbumin (OVA) sensitization, and EA was orally administered for six weeks. Epidermal barrier function, histopathology, immunoglobulins, cytokines, and mitogen-activated protein kinase (MAPK) signaling were evaluated. Pyromeconic acid (PA), a representative constituent of EA, was examined in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Results EA attenuated dermatitis-like lesions and reduced dermatitis scores in OVA-sensitized mice. EA decreased transepidermal water loss, increased skin hydration, restored filaggrin expression, and reduced epidermal and dermal thickening, mast cell infiltration, CD4+/CD8+ T-cell accumulation, splenomegaly, serum total and OVA-specific IgE, and skin interleukin-4 and interleukin-13 levels. EA also reduced extracellular signal-regulated kinase and p38 phosphorylation and interleukin-1β expression in dorsal skin. PA suppressed MAPK activation and inflammatory mediator expression in LPS-stimulated macrophages. Discussion and conclusion EA attenuated OVA-induced atopic dermatitis-like inflammation in association with improved epidermal barrier function, reduced Th2-associated immune responses, and attenuated MAPK signaling. PA showed anti-inflammatory activity in vitro, although its contribution to the in vivo effects of EA remains to be established. EA warrants further investigation as a plant-derived candidate for complementary intervention in atopic dermatitis.
Background Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by immune dysregulation and impaired epidermal barrier function. Interleukin-22 (IL-22) contributes to epidermal inflammation and disrupts keratinocyte differentiation, whereas filaggrin is essential for maintaining epidermal barrie...
C. P. Hazlianda, Yunita Sari Pane, Ramona Ds Lubis et al.· Frontiers in Medicine· 0 citations
Ethanolic clove bud extract suppresses CXCL1 mRNA expression in DNCB-induced ACD mice, which supports the anti-inflammatory potential of S. aromaticum as a candidate for ACD management and warrants further investigation into its molecular mechanisms and in vivo safety profile.
Riandini Aisyah, Pantes Irsa Mahendriyansa Puta, Adam Fauzi Akbar et al.· Biomedika· 0 citations
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by immune dysregulation and epidermal barrier dysfunction. The essential oil of Helichrysum (HEO) possesses known anti-inflammatory properties, yet its therapeutic efficacy and underlying mechanisms in AD remain to be fully elucidated. This stu...
Yong-Qi Chen, Zhong-Ying Xu, Li-Ming Mao et al.· Current Issues in Molecular...· 0 citations
Purpose Persistent cutaneous inflammation and oxidative stress drive the promotion stage of skin carcinogenesis. Most evidence for Garcinia mangostana pericarp comes from purified α-mangostin tested in vitro or given systemically. We evaluated whether a standardized crude G. mangostana pericarp extract (GMPE) applied t...
Siswanto Wahab, K. Djawad, Nuril Ilmi et al.· Clinical, Cosmetic and Inves...· 0 citations
BACKGROUND
Atopic dermatitis (AD) is characterized by epidermal barrier impairment and immune-driven inflammation. Strategies that restore barrier architecture while constraining inflammation are of therapeutic interest.
PURPOSE
To evaluate the barrier-reparative and anti-inflammatory effects of β-myrcene (MYR) in ex...
Na-Na Long, You-Wei Zuo, Jian Li et al.· European Journal of Pharmaco...· 0 citations
Atopic dermatitis (AD) features persistent or recurrent skin inflammation, with oxidative stress also implicated in its development. Luteolin (Lut), a flavonoid sourced from plants, has been reported to attenuate inflammatory and oxidative responses; its effects in experimental AD require further characterization. To...
Xue-Fei Du, Jing-Min Li, Z. Mu et al.· ACS Omega· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.